Norwood Abbey to test virosomal delivery
27 January, 2006 by Ruth BeranNorwood Abbey (ASX:NAL) has initiated animal studies for the use of its needle-free injection device for delivering virosomes, potent carriers of antigens for vaccination.
BresaGen executes supply contracts
27 January, 2006 by Helen SchullerAdelaide biotechnology manufacturer BresaGen (ASX:BGN) has executed supply contracts worth AUD$680,000 with WA based junior biotech Caldeon and Brisbane's Tissue Therapies (ASX:TIS).
Virax sanguine on shortfall in $3.1m raising
23 January, 2006 by Helen SchullerMelbourne immunotherapy developer Virax Holdings (ASX:VHL) has raised $3.1 million through a rights issue for the further development of its HIV therapeutic vaccine, falling $700,000 short of the $3.8 million the company planned to raise.
LCT to raise additional US and European capital
23 January, 2006 by Helen SchullerFollowing the successful placement of more than AUD$3 million worth of shares in the US earlier this month, cell therapy company Living Cell Technologies (ASX:LCT) has revealed plans to raise at least a further AUD$8 million through a second tranche of shares in the US and Europe.
Ellex sells property for $4.43m
20 January, 2006 by Helen SchullerAdelaide company Ellex Medical Lasers (ASX:ELX) has signed a contract for the sale of its building in Adelaide for a price of $4.43 million.
Infertility expert appointed Victorian governor
19 January, 2006 by Graeme O'NeillThe Victorian premier, Steve Bracks, has appointed renowned Melbourne endocrinologist Prof David de Kretser, AO, to succeed John Landy as the state's governor.
Clover cancels AIM listing
19 January, 2006 by Ruth BeranSydney-based Clover (ASX:CLV) has applied to the London Stock Exchange to cancel its listing on the Alternative Investment Market (AIM).
New CEO and President for Novogen's US subsidiary
18 January, 2006 by Ruth BeranSydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, has appointed Dr Reinhard Koenig as CEO and president.
Phosphagenics delivers further positive morphine results
18 January, 2006 by Ruth BeranA phase Ib clinical trial of Melbourne-based Phosphagenics' (ASX:POH, AIM:PSG) TPM-01 transdermal delivery system has demonstrated that therapeutic levels of morphine in plasma were achieved and maintained for more than 48 hours using the technology.
Pharmaxis signs first Aridol distributor
18 January, 2006 by Helen SchullerSydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has signed a European distribution agreement for its first product, Aridol.
Skladnev steps down as Polartechnics CEO
17 January, 2006 by Ruth BeranFollowing a board stoush last year and calls by shareholders at the company's AGM for a change in management, Polartechnics (ASX:PLT) CEO Victor Skladnev was yesterday replaced by Ben Dillon.
Australian researchers awarded $1m Pfizer fellowships
13 January, 2006 by Ruth BeranDr Stephen Nutt, based at the Walter and Eliza Hall Institute, and Dr Anthony Hannan, at the Howard Florey Institute, have each been awarded five-year grants of AUD$1 million under the Pfizer Australia Research Fellowship scheme.
C3 clarifies TGA intention to reject ReCell
12 January, 2006 by Ruth BeranTissue engineering specialist Clinical Cell Culture (ASX:CCE, C3) has clarified aspects of its application for approval to market its ReCell product in Australia, following a decision by the Therapeutic Goods Administration (TGA) in December to reject approval for the product.
Novogen's US subsidiary postpones Nasdaq IPO
12 January, 2006 by Ruth BeranSydney-based biopharma Novogen's (ASX:NRT, Nasdaq:NVGN) US subsidiary, Glycotex, is to postpone its IPO on the Nasdaq national market.
NSW forum to explore research ethics review
11 January, 2006 by Staff WritersThe NSW government's health department is to run a series of forums to explain an ethical review of multi-centre research, including progress towards a model of single ethical and scientific review.
